Abstract
Dyslipidemia is common in chronic kidney disease patients and alterations in serum lipid profile vary widely depending on the level of kidney function. We studied two hundred Iraqi patients who were diagnosed as having chronic kidney disease from June 2011 to January 2013. They were given erythropoietin for seven months. One hundred sixty patients (80%) showed response to treatment with an improvement in lipid profile, while the other 40 patients (20%) showed no significant response to treatment. In conclusion, treatment with erythropoietin seems to positively influence the lipid profile in patients with chronic kidney disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
